Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Pancreatic Neoplasms × Epirubicin × Clear all

Phase

Phase 2 2 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 7 Stomach Neoplasms 2 Triple Negative Breast Neoplasms 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Oesophagogastric Cancer 1 Lymphoma, Large B-Cell, Diffuse 1 HER2-negative Breast Cancer 1 Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 12 Fluorouracil 5 Cisplatin 4 Irinotecan 3 Capecitabine 3 nimotuzumab 2 Taxes 2 Phytotherapy 2 Oxaliplatin 2 Albumin-Bound Paclitaxel 2 130-nm albumin-bound paclitaxel 2 surufatinib 1 rubitecan 1 racemetyrosine 1 methylnaltrexone 1 folfirinox 1 camrelizumab 1 Tranexamic Acid 1 Standard of Care 1 Sirolimus 1 Positron Emission Tomography Computed Tomography 1 Phenytoin 1 Paclitaxel 1 Neoadjuvant Therapy 1 NUC-1031 1 Mirtazapine 1 Methoxsalen 1 Magnetic Resonance Spectroscopy 1 Levobupivacaine 1 Leucovorin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00960284 2012-01-13

PACT-7

IRCCS San Raffaele

Phase 2/3 Completed

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡